4,095 Shares in Gilead Sciences, Inc. $GILD Bought by Integrity Alliance LLC.

Integrity Alliance LLC. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 4,095 shares of the biopharmaceutical company’s stock, valued at approximately $503,000.

Other institutional investors also recently bought and sold shares of the company. Ares Financial Consulting LLC bought a new stake in Gilead Sciences in the fourth quarter worth $28,000. Financial Consulate Inc. lifted its position in Gilead Sciences by 85.8% in the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the last quarter. North Star Investment Management Corp. lifted its position in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 86 shares during the last quarter. MTM Investment Management LLC lifted its position in Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 176 shares during the last quarter. Finally, BOCHK Asset Management Ltd bought a new stake in Gilead Sciences in the fourth quarter worth $31,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Leerink Partners lowered their price target on Gilead Sciences from $148.00 to $146.00 in a research report on Friday, May 8th. Wall Street Zen downgraded Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Argus lifted their target price on Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Cantor Fitzgerald decreased their target price on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, April 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $170.00 target price on shares of Gilead Sciences in a research report on Monday, February 23rd. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Gilead Sciences Stock Down 1.3%

Shares of NASDAQ GILD opened at $134.43 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a market capitalization of $166.90 billion, a price-to-earnings ratio of 18.31 and a beta of 0.31. The stock has a 50 day moving average price of $135.30 and a 200 day moving average price of $134.09. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the firm earned $1.81 earnings per share. Gilead Sciences’s revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is 44.69%.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider owned 125,779 shares in the company, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares in the company, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 53,000 shares of company stock worth $7,075,670. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.